Articles with public access mandates - Li-Chuan ChanLearn more
Available somewhere: 34
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
CW Li, SO Lim, W Xia, HH Lee, LC Chan, CW Kuo, KH Khoo, SS Chang, ...
Nature communications 7 (1), 12632, 2016
Mandates: US National Institutes of Health, Susan G. Komen
Mechanisms controlling PD-L1 expression in cancer
JH Cha, LC Chan, CW Li, JL Hsu, MC Hung
Molecular cell 76 (3), 359-370, 2019
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Deubiquitination and stabilization of PD-L1 by CSN5
SO Lim, CW Li, W Xia, JH Cha, LC Chan, Y Wu, SS Chang, WC Lin, ...
Cancer cell 30 (6), 925-939, 2016
Mandates: US National Institutes of Health, Susan G. Komen
Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1
JH Cha, WH Yang, W Xia, Y Wei, LC Chan, SO Lim, CW Li, T Kim, ...
Molecular cell 71 (4), 606-620. e7, 2018
Mandates: US National Institutes of Health
Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1
CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, ...
Cancer cell 33 (2), 187-201. e10, 2018
Mandates: US National Institutes of Health, Susan G. Komen
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth
Y Yang, CW Li, LC Chan, Y Wei, JM Hsu, W Xia, JH Cha, J Hou, JL Hsu, ...
Cell research 28 (8), 862-864, 2018
Mandates: US National Institutes of Health
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
JM Hsu, W Xia, YH Hsu, LC Chan, WH Yu, JH Cha, CT Chen, HW Liao, ...
Nature communications 9 (1), 1908, 2018
Mandates: US National Institutes of Health
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
Q Hu, Y Ye, LC Chan, Y Li, K Liang, A Lin, SD Egranov, Y Zhang, W Xia, ...
Nature immunology 20 (7), 835-851, 2019
Mandates: US Department of Defense, US National Institutes of Health, Cancer …
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
LC Chan, CW Li, W Xia, JM Hsu, HH Lee, JH Cha, HL Wang, WH Yang, ...
The Journal of clinical investigation 129 (8), 3324-3338, 2019
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
YI Yang, JM Hsu, L Sun, LC Chan, CW Li, JL Hsu, Y Wei, W Xia, J Hou, ...
Cell research 29 (1), 83-86, 2019
Mandates: US National Institutes of Health
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Z Jiang, SO Lim, M Yan, JL Hsu, J Yao, Y Wei, SS Chang, H Yamaguchi, ...
The Journal of clinical investigation 131 (8), 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing
LL Sun, RY Yang, CW Li, MK Chen, B Shao, JM Hsu, LC Chan, Y Yang, ...
American journal of cancer research 8 (7), 1307, 2018
Mandates: US National Institutes of Health, National Natural Science Foundation of China
Targeting glycosylated PD-1 induces potent antitumor immunity
L Sun, CW Li, EM Chung, R Yang, YS Kim, AH Park, YJ Lai, Y Yang, ...
Cancer research 80 (11), 2298-2310, 2020
Mandates: US National Institutes of Health, National Natural Science Foundation of …
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
L Nie, Y Wei, F Zhang, YH Hsu, LC Chan, W Xia, B Ke, C Zhu, R Deng, ...
Nature communications 10 (1), 5114, 2019
Mandates: US Department of Energy, US National Institutes of Health, Cancer Prevention …
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
RCE Hsieh, S Krishnan, RC Wu, AR Boda, A Liu, M Winkler, WH Hsu, ...
Science immunology 7 (72), eabl9330, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
YH Hsu, J Yao, LC Chan, TJ Wu, JL Hsu, YF Fang, Y Wei, Y Wu, ...
Cancer research 74 (17), 4822-4835, 2014
Mandates: US National Institutes of Health
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer
B Shao, CW Li, SO Lim, L Sun, YJ Lai, J Hou, C Liu, CW Chang, Y Qiu, ...
American journal of cancer research 8 (9), 1837, 2018
Mandates: US National Institutes of Health
Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers
CC Yang, A LaBaff, Y Wei, L Nie, W Xia, L Huo, H Yamaguchi, YH Hsu, ...
American journal of translational research 7 (6), 1009, 2015
Mandates: US National Institutes of Health, Susan G. Komen
GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers
HW Ko, HH Lee, L Huo, W Xia, CC Yang, JL Hsu, LY Li, CC Lai, LC Chan, ...
Oncotarget 7 (35), 57131, 2016
Mandates: US National Institutes of Health, Susan G. Komen
New approaches on cancer immunotherapy
JH Cha, LC Chan, MS Song, MC Hung
Cold Spring Harbor perspectives in medicine 10 (8), a036863, 2020
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Publication and funding information is determined automatically by a computer program